abrdn Life Sciences Investors $HQL Shares Sold by Uhlmann Price Securities LLC

Uhlmann Price Securities LLC cut its holdings in shares of abrdn Life Sciences Investors (NYSE:HQL) by 13.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,711 shares of the company’s stock after selling 9,232 shares during the period. Uhlmann Price Securities LLC owned 0.21% of abrdn Life Sciences Investors worth $790,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Flagship Harbor Advisors LLC grew its stake in abrdn Life Sciences Investors by 36.1% during the 1st quarter. Flagship Harbor Advisors LLC now owns 340,877 shares of the company’s stock worth $4,326,000 after buying an additional 90,436 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in abrdn Life Sciences Investors by 31.1% in the first quarter. Raymond James Financial Inc. now owns 312,531 shares of the company’s stock worth $3,966,000 after acquiring an additional 74,061 shares in the last quarter. Formidable Asset Management LLC acquired a new stake in abrdn Life Sciences Investors in the first quarter worth about $812,000. Allspring Global Investments Holdings LLC grew its stake in shares of abrdn Life Sciences Investors by 21.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 235,499 shares of the company’s stock worth $3,017,000 after acquiring an additional 42,015 shares during the last quarter. Finally, LPL Financial LLC grew its stake in shares of abrdn Life Sciences Investors by 14.4% during the first quarter. LPL Financial LLC now owns 328,402 shares of the company’s stock worth $4,167,000 after acquiring an additional 41,307 shares during the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Insider Activity

In related news, major shareholder Saba Capital Management, L.P. sold 41,623 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $14.14, for a total value of $588,549.22. Following the completion of the transaction, the insider owned 2,837,633 shares in the company, valued at $40,124,130.62. This trade represents a 1.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 179,906 shares of company stock valued at $2,530,720. 10.06% of the stock is owned by corporate insiders.

abrdn Life Sciences Investors Stock Down 0.3%

Shares of abrdn Life Sciences Investors stock opened at $16.53 on Monday. The company has a 50 day moving average price of $14.59 and a 200 day moving average price of $13.27. abrdn Life Sciences Investors has a 52 week low of $10.55 and a 52 week high of $16.92.

abrdn Life Sciences Investors Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Friday, August 22nd were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $1.68 dividend on an annualized basis and a dividend yield of 10.2%.

abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.